Cargando…

Evolution of Plant-Made Pharmaceuticals

The science and policy of pharmaceuticals produced and/or delivered by plants has evolved over the past twenty-one years from a backyard remedy to regulated, purified products. After seemingly frozen at Phase I human clinical trials with six orally delivered plant-made vaccines not progressing past...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, David R., Penney, Claire A., Majumder, Amrita, Walmsley, Amanda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116187/
https://www.ncbi.nlm.nih.gov/pubmed/21686181
http://dx.doi.org/10.3390/ijms12053220
_version_ 1782206233008144384
author Thomas, David R.
Penney, Claire A.
Majumder, Amrita
Walmsley, Amanda M.
author_facet Thomas, David R.
Penney, Claire A.
Majumder, Amrita
Walmsley, Amanda M.
author_sort Thomas, David R.
collection PubMed
description The science and policy of pharmaceuticals produced and/or delivered by plants has evolved over the past twenty-one years from a backyard remedy to regulated, purified products. After seemingly frozen at Phase I human clinical trials with six orally delivered plant-made vaccines not progressing past this stage over seven years, plant-made pharmaceuticals have made a breakthrough with several purified plant-based products advancing to Phase II trials and beyond. Though fraught with the usual difficulties of pharmaceutical development, pharmaceuticals made by plants have achieved pertinent milestones albeit slowly compared to other pharmaceutical production systems and are now at the cusp of reaching the consumer. Though the current economic climate begs for cautious investment as opposed to trail blazing, it is perhaps a good time to look to the future of plant-made pharmaceutical technology to assist in planning for future developments in order not to slow this technology’s momentum. To encourage continued progress, we highlight the advances made so far by this technology, particularly the change in paradigms, comparing developmental timelines, and summarizing the current status and future possibilities of plant-made pharmaceuticals.
format Online
Article
Text
id pubmed-3116187
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-31161872011-06-16 Evolution of Plant-Made Pharmaceuticals Thomas, David R. Penney, Claire A. Majumder, Amrita Walmsley, Amanda M. Int J Mol Sci Review The science and policy of pharmaceuticals produced and/or delivered by plants has evolved over the past twenty-one years from a backyard remedy to regulated, purified products. After seemingly frozen at Phase I human clinical trials with six orally delivered plant-made vaccines not progressing past this stage over seven years, plant-made pharmaceuticals have made a breakthrough with several purified plant-based products advancing to Phase II trials and beyond. Though fraught with the usual difficulties of pharmaceutical development, pharmaceuticals made by plants have achieved pertinent milestones albeit slowly compared to other pharmaceutical production systems and are now at the cusp of reaching the consumer. Though the current economic climate begs for cautious investment as opposed to trail blazing, it is perhaps a good time to look to the future of plant-made pharmaceutical technology to assist in planning for future developments in order not to slow this technology’s momentum. To encourage continued progress, we highlight the advances made so far by this technology, particularly the change in paradigms, comparing developmental timelines, and summarizing the current status and future possibilities of plant-made pharmaceuticals. Molecular Diversity Preservation International (MDPI) 2011-05-17 /pmc/articles/PMC3116187/ /pubmed/21686181 http://dx.doi.org/10.3390/ijms12053220 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Thomas, David R.
Penney, Claire A.
Majumder, Amrita
Walmsley, Amanda M.
Evolution of Plant-Made Pharmaceuticals
title Evolution of Plant-Made Pharmaceuticals
title_full Evolution of Plant-Made Pharmaceuticals
title_fullStr Evolution of Plant-Made Pharmaceuticals
title_full_unstemmed Evolution of Plant-Made Pharmaceuticals
title_short Evolution of Plant-Made Pharmaceuticals
title_sort evolution of plant-made pharmaceuticals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116187/
https://www.ncbi.nlm.nih.gov/pubmed/21686181
http://dx.doi.org/10.3390/ijms12053220
work_keys_str_mv AT thomasdavidr evolutionofplantmadepharmaceuticals
AT penneyclairea evolutionofplantmadepharmaceuticals
AT majumderamrita evolutionofplantmadepharmaceuticals
AT walmsleyamandam evolutionofplantmadepharmaceuticals